ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting

PRINCETON, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that results from the NEW DAY clinical trial of ILUVIEN^® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in appropriate patients with diabetic macular edema (DME) will be presented in a late-breaking oral presentation during Retina Subspecialty Day 2025, being held October 17-18, 2025 at the American Academy of Ophthalmology (AAO) 2025 Meeting. The results from the NEW DAY trial have been previously reported.

Read more at globenewswire.com